Assembly Biosciences Announces September Conference Participation
August 31 2017 - 7:00AM
Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage
biotechnology company advancing a new class of oral therapeutics
for the treatment of hepatitis B virus (HBV) infection and novel
oral live biotherapeutics for disorders associated with the
microbiome, today announced participation at various upcoming
conferences:
- International HBV Meeting – Washington, DC
Date: September 5, 2017 Poster
Presentation: “Using a Toolbox of New and Established
Mechanistic Assays to Determine How Core Protein Allosteric
Modifiers (CpAMs) Inhibit HBV cccDNA
Production” Presenter: Dawai Cai, PhD.,
Principal Scientist II, Assembly Biosciences
- Citi’s 12th Annual Biotech Conference –
Boston Date: September 6-7, 2017
- Bugs, Drugs and Beyond: Translational Approaches to the
Microbiome – Menlo Park Date:
September 12, 2017 Panel: From Validation to
Regulation: Breaking Down Barriers to Microbiome
Progress Presenter: Miguel Barbosa, PhD.,
Chief Scientific Officer, Microbiome Program, Assembly
Biosciences
- Discovery on Target: Targeting HBV –
Boston Date: September 25, 2017
Panel: Targeting HBV Core Protein to Achieve
Higher Cure Rates Presenter: Richard Colonno,
PhD., Chief Scientific Officer, HBV Program, Assembly
Biosciences
- Cantor Fitzgerald Annual Healthcare Conference
– New York Date: September 25-27, 2017
- Chicago Microbiome – University of Chicago,
Chicago Date: September 26-27,
2017 Presentation: Realizing the Promise of
the Microbiome: Using Rigourous Pharmaceutical Principles of Drug
Development Presenter: Chris Howerton, PhD.,
Head of Microbiome Discovery Platform, Assembly Biosciences
Copies of the poster and presentations will be available in the
Events and Presentations section of the Company’s website at
www.assemblybio.com.
About Assembly BiosciencesAssembly Biosciences,
Inc. is a clinical-stage public biotechnology company developing
two innovative platform programs: an HBV program advancing a new
class of oral therapeutics for the treatment of hepatitis B virus
(HBV) infection and a microbiome program developing novel oral live
biotherapeutics designed to address diseases associated with the
microbiome. Assembly’s HBV program is advancing multiple drug
candidates with the aim of increasing cure rates in patients with
chronic HBV. The company's microbiome program consists of a fully
integrated platform that includes a robust strain identification
and selection process, methods for strain isolation and growth
under current Good Manufacturing Practices and a patent-pending
delivery system, GEMICEL®, which allows for targeted oral delivery
of live biologic and conventional therapies to the lower
gastrointestinal tract. Assembly is developing a robust pipeline of
product candidates in multiple disease indications. For more
information, visit www.assemblybio.com.
Forward-Looking Statement The information in
this press release contains forward-looking statements regarding
future events, including statements about the clinical and
therapeutic potential of Assembly’s development programs. Certain
forward-looking statements may be identified by reference to a
future period or periods or by use of forward-looking terminology
such as “designed” or "developing." Assembly intends such
forward-looking statements to be covered by the safe harbor
provisions contained in Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. Actual results or developments may differ materially
from those projected or implied in these forward-looking
statements. More information about the risks and uncertainties
faced by Assembly are more fully detailed under the heading "Risk
Factors" in Assembly’s Annual Report on Form 10-K for the year
ended December 31, 2016, and Quarterly Report on Form 10-Q for the
quarter ending June 30, 2017 filed with the Securities and Exchange
Commission. Except as required by law, Assembly assumes no
obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contacts
Assembly Biosciences, Inc.
Investors:
Lauren Glaser
(415) 521-3828
lglaser@assemblybio.com
Media:
Barbara Lindheim
(212) 584-2276
barbara@assemblybio.com
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Apr 2023 to Apr 2024